DOTFM, also known as 2,5-dimethoxy-4-trifluoromethylamphetamine, is a psychedelic drug of the phenethylamine, amphetamine, and DOx families related to DOM. It is the ñ-methylated analogue of 2C-TFM. The drug is the most potent known DOx psychedelic.
According to Daniel Trachsel, DOTFM is active as a psychedelic in humans at doses of 0.3 to 1mg (300âÂÂ1,000üg) orally and its duration is not listed. It is the most potent psychedelic of the DOx family, followed by DOB, which has a dose range of 1 to 3mg orally.
DOTFM acts as an agonist at the serotonin 5-HT<sub>2A</sub> and 5-HT<sub>2C</sub> receptors. In drug discrimination tests in rats, DOTFM fully substituted for LSD and was slightly more potent than DOI. In addition, (R)-DOTFM robustly induces the head-twitch response, a behavioral proxy of psychedelic effects, in rodents, with equivalent potency as (R)-DOI. The drug is around twice as potent as 2C-TFM in animal studies.
In contrast to (R)-DOI, which has extraordinarily potent serotonin 5-HT<sub>2A</sub> receptor-mediated anti-inflammatory effects, DOTFM shows no anti-inflammatory effects. The differences between the drugs in this regard appear to be due to differences in functional selectivity at the serotonin 5-HT<sub>2A</sub> receptor.
The chemical synthesis of DOTFM has been described.
Analogues of DOTFM include 2C-TFM, 4C-TFM (TFM-Ariadne; 4C-DOTFM), DOTFE, TFMFly (DOTFM-FLY), and 25TFM-NBOMe, among others.
DOTFM was first synthesized in 1994 by a team at Purdue University led by David E. Nichols. The threshold dose in humans was reported by Alexander Shulgin in his 2011 book ', who cited personal communication with an anonymous individual in 2003 as the source for the information. Subsequently, Daniel Trachsel described a wider dose range in 2013, although did not report its duration.
DOTFM is a controlled substance in Canada under phenethylamine blanket-ban language.